Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: AEGR +41.4% (Aegerion Pharma and QLT Inc (QLTI) agree to merge), QLTI +27.3%, ALLT +3.2% (Radware and Allot Comms held preliminary talks to merge, but discussions never reached an 'official stage', according to Haaretz), PRGO +1.7% (vague takeover speculation)
Select financial related names showing strength: CS +2.3%, DB +2.2%, BCS +2.2%, SAN +1.5%
Select metals/mining stocks trading higher: FCX +2.7%, RIO +2.2%, BHP +1.4%, MT +1.4%, AA +1.4%, BBL+1.3%
Other news: CBYL +18.4% (Carbylan Therapeutics and KalVista Pharma enter definitive share purchase agreement pursuant to which KalVista will become the majority owners of co), EPRS +14.6% (enters into agreement with Zaklady Farmaceutyczne 'Polpharma' S.A.), AKAO +11.7% (cont strength), CANF +8.6% (announces new mechanism of action data indicating Piclidenoson inhibits two inflammatory cytokines), REXX +6% (announces sale of Illinois Basin asset; expects to receive proceeds at closing of ~$40 mln), KMDA +4.9% (Kamada and Shire (SHPG) announce FDA approval on an expanded label for GLASSIA for the treatment of Emphysema due to severe AAT deficiency), MTL +4.3% (appoints Sergey Rezontov as CFO), GLPG +3.1% (provides R&D and pipeline update for FY16), SHPG +1.4% (Kamada (KMDA) and Shire announce FDA approval on an expanded label for GLASSIA for the treatment of Emphysema due to severe AAT deficiency), CELG +1.3% (adds $3 bln to repurchase program), TWTR +0.9% (Twitter invests ~$70 mln into music service SoundCloud, according to Re/Code), VRX +0.9% (appointed Thomas Ross Sr as its lead independent director; confirms new independent directors were elected at Annual Meeting of Shareholders)
Analyst comments: EXAS +12.8% (Mizhuo says possible catalyst may have been an updated USPSTF web page for the group's colon cancer screening recommendations.), X +2.2% (upgraded to Neutral from Underperform at BofA/Merrill)
In reaction to strong earnings/guidance: N/A.
M&A news: AEGR +41.4% (Aegerion Pharma and QLT Inc (QLTI) agree to merge), QLTI +27.3%, ALLT +3.2% (Radware and Allot Comms held preliminary talks to merge, but discussions never reached an 'official stage', according to Haaretz), PRGO +1.7% (vague takeover speculation)
Select financial related names showing strength: CS +2.3%, DB +2.2%, BCS +2.2%, SAN +1.5%
Select metals/mining stocks trading higher: FCX +2.7%, RIO +2.2%, BHP +1.4%, MT +1.4%, AA +1.4%, BBL+1.3%
Other news: CBYL +18.4% (Carbylan Therapeutics and KalVista Pharma enter definitive share purchase agreement pursuant to which KalVista will become the majority owners of co), EPRS +14.6% (enters into agreement with Zaklady Farmaceutyczne 'Polpharma' S.A.), AKAO +11.7% (cont strength), CANF +8.6% (announces new mechanism of action data indicating Piclidenoson inhibits two inflammatory cytokines), REXX +6% (announces sale of Illinois Basin asset; expects to receive proceeds at closing of ~$40 mln), KMDA +4.9% (Kamada and Shire (SHPG) announce FDA approval on an expanded label for GLASSIA for the treatment of Emphysema due to severe AAT deficiency), MTL +4.3% (appoints Sergey Rezontov as CFO), GLPG +3.1% (provides R&D and pipeline update for FY16), SHPG +1.4% (Kamada (KMDA) and Shire announce FDA approval on an expanded label for GLASSIA for the treatment of Emphysema due to severe AAT deficiency), CELG +1.3% (adds $3 bln to repurchase program), TWTR +0.9% (Twitter invests ~$70 mln into music service SoundCloud, according to Re/Code), VRX +0.9% (appointed Thomas Ross Sr as its lead independent director; confirms new independent directors were elected at Annual Meeting of Shareholders)
Analyst comments: EXAS +12.8% (Mizhuo says possible catalyst may have been an updated USPSTF web page for the group's colon cancer screening recommendations.), X +2.2% (upgraded to Neutral from Underperform at BofA/Merrill)